Rheumatology Advance Access originally published online on July 13, 2006
Rheumatology 2006 45(9):1167-1169; doi:10.1093/rheumatology/kel215a
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first two years)
1Nuffield Orthopaedic Centre, Oxford and University of Oxford, Oxford, 2Wirral Hospital NHS Trust, Wirral, 3Aintree University Hospital, Liverpool, 4Wansbeck General Hospital; Freeman Hospital; University of Newcastle upon Tyne, 5National Rheumatoid Arthritis Society, 6Primary Care Rheumatology Society, 7Royal National Hospital for Rheumatic Diseases, Bath, 8Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust, Oswestry, Lewes Health Centre, 9Lewes, 10Arthritis Care, 11Royal College of Nursing Rheumatology Forum and Litchdon Health Centre, Barnstaple, 12Department of Podiatry and Foot Health, and Department of Orthopaedics and Trauma, Hope Hospital, Salford and 13Academic Rheumatology, City Hospital, Nottingham, UK
Correspondence to: R. Luqmani, Consultant Rheumatologist and Senior Lecturer in Rheumatology, Nuffield Orthopaedic Centre, Windmill Road, Oxford OX3 7LD, UK. E-mail: Raashid.luqmani@noc.anglox.nhs.uk
KEY WORDS: Rheumatoid arthritis, Guideline, Management, Disease-modifying anti-rheumatic drug therapy, Multidisciplinary care
| The first 10% of the full text of this article appears below. |
 |
Scope and purpose of the guideline |
|---|
The annual incidence of rheumatoid arthritis (RA) in the UK is
24 per hundred thousand [1]. The current guideline provides practical evidence-based advice on recommended interventions in RA. The objective is to provide a framework of care for managing RA, including control of synovitis, symptom control, self-management, physical functioning, psychosocial functioning and screening/monitoring. The primary target of this guidance is health professionals and managers; however, it is also relevant to patients with RA. The guidance is limited to the first 2 yrs of RA. This is a short summary of the whole guideline. The full guideline is |
Guideline for managing early RA |
|---|
Assessment/planning phase
Deliver, stabilize and monitor care
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. D. W. Kiely, A. K. Brown, C. J. Edwards, D. T. O'Reilly, A. J. K. Ostor, M. Quinn, A. Taggart, P. C. Taylor, R. J. Wakefield, and P. G. Conaghan Contemporary treatment principles for early rheumatoid arthritis: a consensus statement Rheumatology, July 1, 2009; 48(7): 765 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Luqmani, S. Hennell, C. Estrach, D. Basher, F. Birrell, A. Bosworth, F. Burke, C. Callaghan, J. Candal-Couto, C. Fokke, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years) Rheumatology, April 1, 2009; 48(4): 436 - 439. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Deighton, R. O'Mahony, J. Tosh, C. Turner, M. Rudolf, and on behalf of the Guideline Development Group Management of rheumatoid arthritis: summary of NICE guidance BMJ, March 16, 2009; 338(mar16_1): b702 - b702. [Full Text]
|
|
|
|
|
|
A. Hammond, J. Bryan, and A. Hardy Effects of a modular behavioural arthritis education programme: a pragmatic parallel-group randomized controlled trial Rheumatology, November 1, 2008; 47(11): 1712 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Rituximab and {blacktriangledown}abatacept for rheumatoid arthritis DTB, August 1, 2008; 46(8): 57 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Adib, K. Hyrich, J. Thornton, M. Lunt, J. Davidson, J. Gardner-Medwin, H. Foster, E. Baildam, L. Wedderburn, and W. Thomson Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study Rheumatology, July 1, 2008; 47(7): 991 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E H S Choy, C M Smith, V Farewell, D Walker, A Hassell, L Chau, D L Scott, and for the CARDERA (Combination Anti-Rheumatic Drugs Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis Ann Rheum Dis, May 1, 2008; 67(5): 656 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. F. Panoulas, K. M. J. Douglas, H. J. Milionis, A. Stavropoulos-Kalinglou, P. Nightingale, M. D. Kita, A. L. Tselios, G. S. Metsios, M. S. Elisaf, and G. D. Kitas Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis Rheumatology, September 1, 2007; 46(9): 1477 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Combination therapy for early rheumatoid arthritis DTB, November 1, 2006; 44(11): 81 - 85. [Abstract] [Full Text] [PDF]
|
|